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Abstract: Cytokine and chemokine levels in body fluid provide information of altered conditions in patients. The parallel 
analysis of multiple factors, such as cytokines, from small sample sizes is an interesting approach for the assessment of in 
vivo activation signatures and functionality after ex vivo stimulation. One interesting application is for therapy monitoring—
such as safety data, pharmacodynamics, evidences for mode-of-action and side effects—which is particularly useful for 
accompanying early phase clinical trials. There are different platforms for multiplex analyses of ligands available. An assay 
validation of three different platforms for simultaneous quantification of cytokines (Luminex Bio-Plex® 200, Meso Scale 
Discovery® and Ella®) was performed in this study. The comparison of multiplex platforms, which use different ways of 
achieving parallel measurements of biomarkers, reveal the performance strengths and weaknesses. We showed examples of 
in-house assessments of intra- and inter-assay variations, determination of the range and recovery of classical immunological 
serum markers and discussed advantages and disadvantages of these three platforms in relation to the question addressed. 
All the platforms show low intra-assay variances. The Luminex platform shows a high inter-assay variance for the majority 
of parameters, whereas the MSD and Ella platforms show low inter-assay variances.
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Introduction
Soluble factors circulating in the body, such as in peripheral blood, urine and liquor, are effective sources for evaluating cell/tissue-based activity 
useful for diagnostics and patient stratification[1,2]. 
Cytokines,  chemokines and growth factors are 
important factors in cell communication, activation and 
differentiation. Alterations in their pattern could provide 
valuable information and allow the evaluation of health 
condition. In order to obtain a clinical evaluation, several 
factors need to be considered: levels of circulating 
soluble factors reflect, in most cases, an excess of locally 
produced mediators and are therefore an early indicator 
of changes in the homeostasis but might not always 
reflect locally restricted clinical situations. Furthermore, 
the measurement usually reflects only the state at the 
time point (snapshot) the sample was obtained and 
different pathological situations show a distinct secretion 
pattern. Most importantly, in the majority of clinical 
evaluations, more than one biomarker needs to be 
available to support the interpretation of the activation 
state and clinical course[3]. 
Profiling these soluble factors is an important part 
in routine diagnostics for intensive care units and as a 
safety and exploratory parameter in clinical studies to 
obtain the current stage of the immune response after 
infections, vaccination or therapeutic intervention.
The ELISA system is the most common method 
to determine the quantitative changes of cytokines/
chemokines[4]. Due to the limitation of the classic 
method, only one parameter per run can be analysed. The 
only possibility to analyse more than one parameter with 
this conventional method is to measure several ELISAs 
one after the other. However, this might face another 
problem if the source of samples is limited in volume 
and has resource issues as well. Therefore, several 
multiplex technologies were developed to quantify 
simultaneously the concentration of multiple analytes. 
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Multiplex technologies allow a wide-range screening 
with very small sample volumes. 
In this study, we compared the validation of three 
different multiplex technologies based on different 
platforms: the Luminex Bio-Plex® 200 System, BioRad® 
(Luminex Corp., Texas, USA) technology, the Meso 
Scale Discovery® (Meso Scale Diagnostics, Maryland, 
USA) technology and the Ella® (ProteinSimple, 
California, USA) technology[5]. The performances of 
each of these technologies were evaluated in accordance 
with the international guidelines of ICH/GCP under 
“Validation of Analytical Procedures”[6].
The Luminex Biorad Bio-plex® 200 platform can 
analyse theoretically up to 100 analytes in parallel and 
works on a bead-based sandwich ELISA principle. 
Instead of 96-well plates as a solid phase for the binding 
of capture antibodies as in the classic ELISA system, 
the Luminex concept is the simultaneous measurement 
of multiple analytes by using differentially color-coded 
beads. Each bead type is characterized by a unique 
emission wavelength when excited by the red laser 
(660 nm). Cytokine-specific capture antibodies are then 
bound to a particularly coded bead. Quantitation is 
accomplished by a sandwich assay using a fluorescently 
labelled detection antibody with an emission wavelength 
of 532 nm when excited by the red laser. Multiple 
readings on each bead set further validate the results[7]. 
The principle of the Meso Scale Discovery (MSD) 
method is based on linking capture antibodies to the 
solid phase on ten specific carbon spots per well of a 96-
well plate. The detection antibody is linked with a sulfo-
tag and upon electronical stimulation, the sulfo-tag leads 
to light emission. This electrochemiluminescence is 
detected and measured with a CCD camera[8]. 
The concept of the Ella system is rather an automated 
multi-analysis system based on a microfluidic cartridge 
than a real multiplex system. The cartridges used by 
the Ella system separate the sample into four nano-
capillaries. While migrating through microfluidic 
channels, it subsequently passes specific capture 
antibodies, then passes the detection antibody and is 
finally scanned in the glass nano-reactor where the 
fluorescence intensities are measured. In contrast to the 
Luminex and MSD technology, the standard values of 
the Ella system are provided by the company for each lot 
of cartridge[9]. 
We performed a detailed validation of the novel 
multiplex platforms and compared the performance 
of the quality controls, the standard curve and the 
robustness of the method for ex vivo-stimulated whole 
blood samples. The multiplex platforms have different 
properties; therefore, the parameters for the validation 
were chosen for each platform with special regards to 
their applicability in clinical trials and diagnostics[10].
Material and Method
Cell Stimulation
Whole Heparin blood from healthy volunteers was 
stimulated with 0,1 ng/mL LPS for 24 h at 37 °C. 
After centrifugation for 15 min at 1,000 × g at room 
temperature (RT), the supernatant (blood plasma) was 
collected and aliquoted. The whole Heparin blood was 
stimulated with 25 ug/ml Concavalin A (ConA) for 
24 h at 37 °C, 1:10 diluted with serum matrix, and the 
concentration of IFN-g, IL-17A, IL-2 and IL-5 was 
measured on the Ella platform. 
Luminex Method
The human Luminex kit is custom-designed (for IFN-γ, 
IL-10, IL-1β, IL-6, IL-8, IP-10, MCP-1 and TNF-α) 
and was purchased from Millipore® (Merck Millipore, 
Darmstadt, Germany). The Luminex kits provide ready-
to-use cocktails of the respective cytokine analytes as 
standard for the assay. The standard was reconstituted 
with 250 µL deionized water to obtain a concentration of 
10000 pg/mL for all cytokines. The vials were inverted 
multiple times for mixing. After vortexing, the vials 
were kept for 5–10 min at RT and then on ice until use. 
Preparation of further serial 1:5 dilution of Cytokine 
Standard was done with expected final concentrations of 
2000 pg/mL, 400 pg/mL, 80 pg/mL, 16 pg/mL and 3.2 
pg/mL. Quality Controls (low and high) are components 
of the kits and the respective Quality Control ranges are 
provided by the manufacturer. The two Quality Controls 
(low and high) were reconstituted with 250 µL deionized 
water (low and high). The vials were inverted multiple 
times for mixing and, after vortexing, the vials were 
kept for 5–10 min at RT and then on ice until use. The 
samples were measured on a suspension array multiplex 
system (Bio-Plex® 200 System, BioRad®). The Bio-Plex 
Manager Software controls the instrument, acquires and 
analyses data without the need to import files. Analysed 
data can then be exported as Excel files.
ELLA Method
The human inflammatory kit (for IL-10, IL-12p40, IL-
1β and IL-6) and the T cell activation kit (for IFN-γ, IL-
17A, IL-2 and IL-5) for the Ella system were purchased 
from ProteinSimple. The Ella system runs a maximum 
of four parameters in triplicates on a 16-well cartridge. 
The standard is generated by the factory and is provided 
lot-wise. The 5PL curve is an average of five replicates 
of each standard value. The information of the factory-
standard curve is encoded in the barcode on each 
cartridge. The cartridges contain the capture antibodies, 
biotinylated detection antibodies and the streptavidin-
dye conjugate in the appropriate area of the cartridges. 
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Quality Controls (low and high) are components of the 
kits and respective Quality Control ranges are provided 
by the manufacturer. Quality Controls (low and high) 
were reconstituted with the respective volume of 
deionized water. The vials were inverted multiple times 
for mixing. After vortexing, the vials were kept for 5–10 
min at RT and then on ice until use. 
MSD Method
The human Proinflammatory Panel 1 kit (for IFN-γ, 
IL-10, IL-2, IL-4 and TNF-α) was purchased from 
MSD. The kit provides all reagents, together with 
a 96-well plate with specific pre-coated spots, the 
detection antibodies and assay diluent. The standard 
was reconstituted with assay diluent to obtain a lot-
specific concentration which differs for all cytokines. 
The vials were inverted multiple times for mixing and, 
after vortexing, the vials were kept for 5–10 min at RT 
and then on ice until use. Preparation of further serial 1:5 
dilution of Cytokine Standard was performed. Quality 
Controls (low and high) are components of the kits and 
respective Quality Control ranges are provided by the 
manufacturer. The Quality Controls (low and high) were 
reconstituted with 250 µl of deionized water. The vials 
were inverted multiple times for mixing. After vortexing, 
the vials were kept for 5–10 min at RT and then on ice 
until use.
Accuracy
The accuracy of a measurement system is the degree 
of closeness of measurements of a quantity to its actual 
(true) value. Accuracy is the combination of precision 
and repeatability.
Precision
Repeatability (intra-assay variation) is defined as the 
degree of precision of multiple measurements using the 
same test conditions (e.g. identical sample material, and 
analysis conducted by the same analyst on the same day 
using identical equipment). Intermediate precision (inter-
assay variation) is defined as the degree of precision of 
multiple measurements using varying conditions within 
the same lab (e.g. same material tested on multiple 
days by multiple analysts). Intra-assay and inter-assay 
variations were assessed as described below. For inter-
assay variation, plasma samples from three stimulated 
donors were analysed on five independent days. For 
intra-assay variation, plasma from three stimulated 
donors in ten replicates were analysed on the same day. 
Calculation
For each sample, respective OD values were obtained 
by subtracting the blank. A respective calibration 
curve was used to determine the corresponding 
analyte concentration of the OD values. The mean 
concentrations and standard deviations of the samples 
were calculated. As a measure for the intra-assay and 
inter-assay precision, the percentage of coefficient of 
variation (CV) was calculated for each analyte:
% CV = standard deviation (SD) / mean concentration c̅ × 100
Statistics
The analysed data was exported from the platform-
specific software as Excel file and further statistical 
data analysis was performed by using Prism Software 
(GraphPad® version 6.0).
Ethics
The study was approved by the local ethics committees 
(application number: EA2/152/16). All healthy 
volunteers in the study provided written informed 
consent before blood donation.
Results
Quantification Limits of the Standards
The Luminex standards from Milliplex® (Merck 
Millipore) were 1:5 diluted to generate a six-point 
standard curve. All analytes started with the same 
stock concentration of 10000 pg/mL. According to the 
manufacturer, the detection range of TNF-α, MCP-1, IP-
10, IL-8, IL-6, IL-1β, IL-10 and IFN-γ is from 10000 pg/
mL – 3,2 pg/mL (Figure 1A). 
The MSD standards (Meso Scale Diagnostics) were 
1:4 diluted to generate a seven-point standard. The stock 
concentration for the analytes differed between the 
analytes. The detection ranges were as follows: TNF-α 
313 pg/mL – 0,08 pg/mL, IL-4 240 pg/mL – 0,06 pg/
ml, IL-2 1220 pg/mL – 0,30 pg/mL, IL-10 307 pg/mL – 
0,07 pg/mL and IFG-g 1270 pg/mL – 0,31 pg/mL (Figure 
1B). Compared to the Luminex system, the MSD starts 
with a lower stock concentration and therefore detects 
values inside a lower concentration range. However, 
the detection ranges of the MSD span an overall larger 
range compared to the Luminex platform since it reaches 
a far lower sensitivity. The Luminex platform shows a 
signal range over four logs, whereas the MSD platform 
detects a range over five logs. The Ella platform 
provides a standard detection range over six logs, 
according to manufacturer, and thereby covers the high 
concentration and the lower concentration range. The 
lower limit of quantification (LLOQ) and upper limit 
of quantification (ULOQ) of Luminex and MSD were 
calculated by using the mean of five standard curves 
from individual experiments of the same kit. Since the 
standard performance for the ELLA platform is assessed 
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by the company, we generated the LLOQ by diluting 
the controls. The ULOQ could not be assessed with the 
standard. Table 1 shows the lower and upper limits of 
quantification.
Comparison of Control Variability of the 
Different Platforms
To receive information about the accuracy of the 
measurement, all three platforms offer quality controls 
with different concentrations. The MSD platform 
provides high, medium and low quality controls 
covering a broader range compared to both of the other 
platforms with only two controls of high and low. The 
concentrations for the MSD high and medium controls 
are however comparable to the high and low controls 
of the competitors, whereas the MSD low control is 
significantly lower. We calculated the percentage of 
variation coefficient (% CV) by using the mean of five 
independent experiments of the same platform-specific 
control lot for all three platforms (see Figure 2A–C). 
The % CV of the Luminex platform for the high 
control was below our acceptance criteria of 25% for 
TNF-α, MCP-1, IP-10, IL-6, IL-1β, IL-10 and IFN-γ. 
However, the % CV of IL-8 showed rates above our 
acceptance criteria of 25%. For the low concentration 
control, the variation coefficient was lower than our 
acceptance criteria of 25% for TNF-α, MCP-1, IP-10, 
IL-6, IL-1β and IL-8, but not for IFN-γ and IL-10 (Figure 
2A). 
The variation coefficient of the MSD platform for the 
high and medium control was below our acceptance 
criteria of 25% for all analysed cytokines (TNF-α, IL-4, 
IL-2, IL-10 and IFN-γ). In contrast, for the low controls, 
all cytokines failed to satisfy our acceptance criteria of a 
% CV below 25% (Figure 2B). 
The % CVs of the Ella platform for high and low 
control were lower than the acceptance criteria of 25% 
for the inflammatory kit (IL-10, IL-12p70, IL-1β and IL-
6) and for the T cell activation kit (IFN-g, IL-17A, IL-2 
and IL-5) (Figure 2C).
Comparison of Spike Recovery of the Controls
To compare the recovery rate of the three platforms, the 
control samples with an expected control range were 
measured. To determine the control recovery rate of the 
detected spiked concentration, the percentage of the 
recovered concentration related to the expected 100% 
concentration was calculated. Our acceptance criteria 
for accuracy of recovery were fulfilled if the measured 
concentration differed only ± 25% from the expected 
concentration. 
The Luminex high control was below our acceptance 
criteria of 25% for all analysed cytokines (TNF-α, MCP-
1, IP-10, IL-8, IL-6, IL-1β, IL-10 and IFN-γ. The low 
control was below our acceptance criteria of 25% for 
most of the analysed cytokines (TNF-α, MCP-1, IP-10, 
IL-8, IL-6, IL-1β and IFN-γ), apart from IL-10 (Figure 
3A). The MSD high, middle and low control fulfilled the 
acceptance criteria for IFN-γ, IL-10 and IL-4. However, 
the recovery rate for TNF-α and IL-2 did not meet the 
acceptance criteria for high, middle and low control 
(Figure 3B). The Ella platform fulfilled the acceptance 
criteria for high and low control (Figure 3C) for the 
inflammatory kit (IL-10, IL-12p70, IL-1β and IL-6) as 
much as for the T cell activation kit (IFN-γ, IL-17A, 
IL-2 and IL-5).
The Intra-Assay Precision of Cytokines from 
Stimulated Whole Blood
So far, we have only used the controls and standards 
provided by the manufacturer to evaluate the assay 
performance. In order to simulate patient samples better, 
we stimulated the whole blood with either 0.1 pg/mL 
LPS or with 25 ug/mL ConA. The stimulated whole 
blood is a relevant test to simulate the physiological 
immune response with medium to high levels of cytokine 
Figure 1. Standard curves demonstrating the range of detection 
of the signal and the concentration of the Luminex platform (A) 
and the MSD platform (B). Standard curve for the ELLA platform 
was not performed during the daily measurement; data were 
provided by factory-generated standard. The standard curves 
were measured on five different days and the error bars show the 
standard deviation (SD) of the mean.
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responses. Additionally, the intra-assay variability of all 
platforms of Luminex (Figure 4A), MSD (Figure 4B) 
and the inflammatory and T cell activation kit from Ella 
were assessed (Figure 4C). The intra-assay variability 
was determined as the percentage of variability (% CV) 
from ten replicates of the stimulated samples. The % CV 
of all platforms remained below the acceptance criterion 
of <25% CV and showed a good intra-assay precision.
The Inter-Assay Precision of Stimulated Whole 
Blood
The inter-assay variability was determined by measuring 
samples of stimulated whole blood on five consecutive 
days. The percentage of variation coefficient (% CV) 
was calculated to establish the inter-assay precision 
with an acceptance criterion of <25% CV. The Luminex 
platform showed a variation coefficient below 25% for 
IL-8 and TNF-α and fulfilled our acceptance criterion. 
However, none of the other parameters, i.e. MCP-1, IP-
10, IL-6, IL-1β, IL-10 and IFN-γ matched our inter-
assay precision criterion (Figure 5A). The MSD platform 
fulfilled the inter-assay acceptance criterion for TNF-α, 
IL-2, IL-10 and IFN-γ. The high % CV for the IL-4 
measured on the MSD platform was due to the absence 
of higher IL-4 concentrations after LPS stimulation 
(Figure 5B). The Ella platform showed an excellent 
inter-assay precision for the inflammatory kit (IL-10, 
IL-12p70, IL-1β and IL-6) as much as for the T cell 
activation kit (IFN-γ, IL-17A, IL-2 and IL-5) with an 
inter-assay variance even below 20% CV (Figure 5C).
Table 1. Limits of LLOQ and ULOQ provided by the company in comparison to in-house generated data 
Luminex
Analyte
LLOQ (pg/mL) ULOQ (pg/mL)
Company In-house Company In-house
IFN-y N/A 3.20 N/A 9997.63
IL-10 N/A 3.18 N/A 10010.73
IL-1β N/A 3.21 N/A 9798.76
IL-6 N/A 3.20 N/A 4292.48
IP-10 N/A 7.16 N/A 10008.52
IL-8 N/A 3.22 N/A 2046.70
MCP-1 N/A 3.25 N/A 3439.38
TNF-α N/A 3.22 N/A 6766.02
MSD
Analyte
LLOQ (pg/mL) ULOQ (pg/mL)
Company In-house Company In-house
IFN-y 7.47 1.48 938.0 1312.2
IL-10 0.68 1.10 233.0 80.2
IL-2 0.89 4.34 938.0 1253.4
IL-4 0.45 0.94 488.0 244.6
TNF-α 0.69 1.15 248.0 326.3
Ella
Analyte
LLOQ (pg/mL) ULOQ (pg/mL)
Company In-house Company In-house
IL-10 0.46 2.88 5530.0 N/A
IL-12p70 0.46 2.95 2570.0 N/A
IL-1β 0.41 4.12 3850.0 N/A
IL-6 0.41 3.24 3850.0 N/A
IFN-y 1.16 20.24 6050.0 N/A
IL-2 0.64 141.85 990.0 N/A
IL-5 0.07 1.80 3120.0 N/A
IL-17A 0.82 27.63 8490.0 N/A
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Figure 2. Variability of quality controls of the different platforms. 
To evaluate the quality of a run, all platforms offer quality 
controls, which have to meet a specific range. The inter-assay 
variance of the controls of the Luminex platform (A), the MSD 
platform (B) and the Ella platform (C) are shown as the percentage 
coefficient of variance (% CV). The control concentrations of the 
Luminex and Ella platforms were comparable for the high and 
low control. The MSD high control was comparable to the other 
platforms, the MSD medium control was comparable to the low 
control of the other platforms. The MSD low control was clearly 
lower compared to the competitors. 
Figure 3. Recovery rates in different platforms with different 
concentrations of the Luminex (A), MSD (B) and Ella (C) kits. 
The mean of the measured control was analysed five times for all 
platforms with an expected concentration of ± 25% of the actual 
concentration. The acceptance range is displayed with dotted lines 
on each graph. 
Discussion
Immunological monitoring of patients during clinical 
studies with, for instance, new biologicals which target 
the immune system, is of high relevance for obtaining 
sufficient data about the immune status of these patients. 
Many studies in the past have tried to inhibit the immune 
system for treating chronic inflammatory diseases such 
as rheumatoid arthritis[11] or psoriasis[12], or to treat 
cancer by using checkpoint inhibitors[13]. The changes 
in levels of immune mediators provide insights into 
the pharmacodynamics of drugs, and this might help to 
understand why drugs have failed to meet their clinical 
target. This allows us to learn from the potential failure 
of drugs and to re-adapt attempts aiming to modulate 
the immune system more precisely[14]. Furthermore, 
monitoring of immunological mediators is important 
also for safety reasons and for the understanding/
interpretation of side effects[15]. 
In order to achieve a more complete picture in order 
to allow an adequate interpretation of data, several 
multiplex analysis platforms have been developed, which 
allow the parallel analysis of multiple analytes from 
small amounts of material. We have compared three 
commonly used systems, which differ in their principles 
of achieving this goal, as much as in the number of 
different analytes they can handle in parallel. 
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Figure 4. The intra-assay variability of the different platforms of 
ten replicates was measured on the same day. Whole blood was 
stimulated with 0,1 ng/mL LPS, 1:10 diluted with serum matrix 
and measured on the Luminex platform to assess the concentration 
of IFN-γ, IL-10, IL-1β, IL-6, IL-8, IP-10, MCP-1 and TNF-α 
(A). Whole blood was stimulated with 0,1 ng/ml LPS, 1:10 
diluted with serum matrix and measured on the MSD platform 
to determine the concentration of IFN-γ, IL-10, IL-2, IL-4 and 
TNF-α (B). Whole blood was stimulated with 200 ng/mL LPS, 1:10 
diluted with serum matrix and run on the Ella platform to measure 
the concentration of IL-10, IL-12p70, IL-1 and IL-6; whole blood 
was stimulated with 25 ug/mL ConA, 1:10 diluted with serum 
matrix and the concentration of IFN-γ, IL-17A, IL-2 and IL-5 was 
measured on the Ella platform (C). Intra-assay variability was 
calculated with % CV for ten replicates and the dotted line shows 
the acceptance criteria.
Figure 5. The inter-assay variability of the different platforms 
of duplicates measured on five consecutive days. Whole blood 
was stimulated with 0,1 ng/mL LPS, 1:10 diluted with serum 
matrix and measured on the Luminex platform to assess the 
concentration of IFN-γ, IL-10, IL-1β, IL-6, IL-8, IP-10, MCP-
1 and TNF-α (A). Whole blood was stimulated with 0,1 ng/mL 
LPS, 1:10 diluted with serum matrix and measured on the MSD 
platform to determine the concentration of IFN-γ, IL-10, IL-2, 
IL-4 and TNF-α (B). Whole blood was stimulated with 0,1 ng/ml 
LPS, 1:10 diluted with serum matrix and the concentration of IL-
10, IL-12p70, IL-1β and IL-6 was measured on the Ella platform; 
whole blood was stimulated with 25 ug/mL ConA, 1:10 diluted 
with serum matrix and the concentration of IFN-g, IL-17A, IL-2 
and IL-5 was measured on the Ella platform (C). Intra-assay 
variability was calculated with % CV for 10 replicates and the 
dotted line shows the acceptance criteria.
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Our data show that each platform is useful and has its 
own advantages as well as limitations. Therefore, it is 
very important to select the right platform depending on 
the questions being addressed.
The Luminex platform is based on colour-coded beads, 
which provide the basis for up to 100 different parallel 
sandwich ELISAs from the same sample[7]. The MSD 
platform links up to ten different capture antibodies on 
defined spots in a 96-well format and then uses a highly 
sensitive electrochemiluminescence which exploits the 
company’s patented sulfo-tag detection system[8]. The 
most recently developed ELLA system by ProteinSimple 
exploits a microfluidic system, which in fact distributes 
the sample to different classical single-plex ELISAs 
based on the established ELISA detection of R&D 
Systems®[9]. So far, the system is restricted to measure 
only four analytes in parallel as triplicates. 
In order to obtain highly reliable data from these 
kinds of analyses, several aspects have to be validated 
in-house by the laboratory according to the guidelines 
of the regulatory agencies[6]. Currently, none of the 
companies provide In-Vitro Diagnostic (IVD)-certified 
assays. Furthermore, one disadvantage of using 
multiplex analyses is that each individual combination 
of analytes needs validation, since the combination used 
can have an impact on specificity and performance. In 
this study, we focused mainly on aspects of precision: 
the variation of test results with the same sample 
was analysed in parallel on the same day (intra-assay 
variance), and the variation of test results with the same 
sample was analysed on different days (inter-assay 
variance). Particularly, the inter-assay variance is of 
high importance for clinical studies in order to obtain 
comparable results from the patient in the follow-up 
during the observation period. The companies provide 
some information about their own experimental variation 
between day-to-day inter-assay variances. However, 
our own data showed some differences. The larger 
variation we observed might be caused mainly by two 
reasons: 1) We had used not only the companies’ control 
samples (mostly recombinant proteins, which also in our 
experience showed a relatively small variation in most 
cases) but also supernatants from ex vivo stimulated 
whole blood. These samples reflect patient samples 
better and also incorporate the intrinsic problem that 
the concentration of a particular cytokine is not always 
in the optimal range where the variation of the assay 
would be smaller. This was also reflected by the fact 
that the variation for the low concentration control by 
MSD was higher than the one for the middle and high 
controls. 2) We had used manual pipetting only, without 
any automated support. Variation of the assays might 
be smaller if pipetting automatization were used. This 
might be one of the reasons why the ELLA system 
had the lowest inter-assay variance, because right after 
sample application, the entire further processing is fully 
automatized on this platform. Another aspect of ELLA is 
the multiplexing in separate circuits for each parameter, 
preventing undesired ligand/antibody interactions.
Conclusion
The acceptance criteria of assay variation below 25% CV 
is rather arbitrary, although suggested by the regulatory 
agencies[6]. Whether this value is of real biological or 
even clinical relevance is a matter of debate. Many 
cytokines would impact on the physiological outcome 
only if they are elevated by a factor of ten or more, and 
therefore also assay variations of more than 25% CV 
would still allow an interpretation of data and could 
still be used at least for exploratory studies. However, 
this must be taken into account in the interpretation of 
changes. Nevertheless, it is still very much appreciated 
if the assay variation is as low as possible, and therefore 
the ELLA system by ProteinSimple seems to be the most 
reliable platform.
However, the disadvantage of the ELLA system 
is that it allows only the lowest number of analytes 
(four parameters) to be measured in parallel. Here, the 
Luminex system outperforms the other two providers 
clearly. Therefore, it might be the best way to select 
suitable biomarkers in a pre-study with the platform, 
which allows the highest number of mediators to be 
analysed in parallel and then to reduce the number of 
analytes to a number which can be handled by platforms 
with a particularly low inter-assay variance for the 
clinical study itself. 
Another important aspect of choosing an appropriate 
platform is the question of what kind of concentration 
range can be analysed by the system. If the range is 
relatively low, it could cause a repeated measurement 
of a sample at another dilution, which would drive up 
costs and necessary manpower. This is particularly an 
issue if the concentration of cytokines inside the same 
sample is very different. Thus, IFNγ for instance can 
be quite strongly induced in human samples (up to ng 
range) whereas IL-4 is hardly detectable. If one wants 
to analyse both cytokines inside the same sample, then 
the sensitivity of the cytokine assays has to be adapted 
to each other or the range has to cover very low and 
very high concentrations. None of the assays tested here 
were designed to adapt different cytokine sensitivities, 
and therefore the range is the decisive parameter. The 
Luminex platform shows a signal range over four logs, 
whereas the MSD platform detects a range over five 
logs. The Ella platform provides a standard detection 
range over six logs, according to the manufacturer’s 
information, and thereby covers the high concentration 
and the lower concentration range best.
Akyüz L, et. al.
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